Schering’s U.S. sales power first quarter
Sales of drugs and contrast agents in the U.S. drove German pharmaceuticals maker Schering to what it called an “exceptionally good” first quarter 2000, the company said last week.U.S. sales grew by 49% to 231 million euros, accounting for 22%
Sales of drugs and contrast agents in the U.S. drove German pharmaceuticals maker Schering to what it called an exceptionally good first quarter 2000, the company said last week.
U.S. sales grew by 49% to 231 million euros, accounting for 22% of Scherings total sales, which were reported up 25% to 1.044 billion euros. Net profit was up 22% to 106 million euros ($97.5 million) in the period from January to March.
The companys diagnostics division, which is one of the worlds largest makers of contrast agents, showed a sales increase of 27% to 295 million euros. Schering also makes a best-selling multiple sclerosis drug, Betaferon, and is a leading manufacturer of contraceptives and fertility drugs.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
